Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SPRC

SciSparc Ltd

Apr 25 • 04:00PM ET

1.26

Dollar change +0.05
Percentage change 4.13	%

Healthcare • Biotechnology • Israel • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.34	Insider Own	0.02%	Shs Outstand	2.45M	Perf Week	-2.33%
Market Cap	3.09M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.45M	Perf Month	-32.26%
Income	-5.12M	PEG	-	EPS next Q	-	Inst Own	2.56%	Short Float	21.38%	Perf Quarter	-79.45%
Sales	2.88M	P/S	1.07	EPS this Y	-	Inst Trans	-	Short Ratio	0.62	Perf Half Y	-73.64%
Book/sh	10.77	P/B	0.12	EPS next Y	-	ROA	-47.02%	Short Interest	0.52M	Perf Year	-93.18%
Cash/sh	2.10	P/C	0.60	EPS next 5Y	-	ROE	-72.84%	52W Range	1.15 - 23.66	Perf YTD	-74.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.28%	ROI	-67.06%	52W High	-94.67%	Beta	1.34
Dividend TTM	-	Quick Ratio	3.63	Sales past 5Y	22.75%	Gross Margin	47.12%	52W Low	9.57%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	4.10	EPS Y/Y TTM	61.54%	Oper. Margin	-220.81%	RSI (14)	24.74	Volatility	5.92% 7.58%
Employees	4	Debt/Eq	0.01	Sales Y/Y TTM	113.73%	Profit Margin	-177.91%	Recom	1.00	Target Price	520.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.15	Prev Close	1.21
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	849.28K	Price	1.26
SMA20	-20.34%	SMA50	-50.50%	SMA200	-75.68%	Trades		Volume	129,567	Change	4.13%

Apr-11-24 08:15AM	SciSparc to Acquire AutoMax (GlobeNewswire) +6.25%
Mar-27-24 09:12AM	Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire) -6.45%
08:55AM	SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (GlobeNewswire)
Mar-21-24 08:58AM	SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research (GlobeNewswire)
Mar-18-24 07:29AM	SciSparc Granted Another Patent, Strengthening its Core Technology in Canada (GlobeNewswire)
08:49AM	Loading…
Mar-14-24 08:49AM	SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial (GlobeNewswire) -7.50%
Mar-12-24 08:14AM	SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure (GlobeNewswire) -8.78%
Mar-08-24 07:11AM	SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder (GlobeNewswire) -6.11%
Mar-07-24 07:49AM	SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe (GlobeNewswire)
Mar-06-24 04:41PM	SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology (GlobeNewswire)
Feb-29-24 08:35AM	SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing (GlobeNewswire)
Feb-27-24 09:30AM	EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds (Benzinga)
07:58AM	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
07:58AM	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
Feb-20-24 07:14AM	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire) +15.52%
07:14AM	Loading…
07:14AM	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire)
Jan-29-24 07:18AM	SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder (GlobeNewswire) -15.43%
Jan-24-24 01:49PM	Why Is SciSparc (SPRC) Stock Up 50% Today? (InvestorPlace) +78.03%
07:42AM	SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement (GlobeNewswire)
Jan-19-24 09:28AM	SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million (GlobeNewswire) -8.77%
Jan-04-24 07:18AM	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments (GlobeNewswire) -8.02%
07:18AM	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments (GlobeNewswire)
Dec-13-23 02:02PM	Why Is SciSparc (SPRC) Stock Up 25% Today? (InvestorPlace) +39.51%
08:18AM	SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform (GlobeNewswire)
Dec-07-23 09:05AM	SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel (GlobeNewswire) -6.12%
Dec-05-23 08:47AM	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment (GlobeNewswire)
Dec-01-23 08:14AM	Weight Loss Treatment: SciSparc's Obesity Drug Showed Positive Results in a Pre-Clinical Trial (GlobeNewswire)
Nov-28-23 08:55AM	SciSparc Adopts Limited Duration Shareholder Rights Plan (GlobeNewswire) -9.22%
08:25AM	SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment (GlobeNewswire)
Nov-27-23 08:41AM	SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform (GlobeNewswire)
08:55AM	Loading…
Nov-24-23 08:55AM	New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder (GlobeNewswire) +35.22%
Nov-22-23 09:49AM	Why Is SciSparc (SPRC) Stock Up 20% Today? (InvestorPlace) +16.80%
07:42AM	SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel (GlobeNewswire)
Nov-15-23 10:55AM	Why Is SciSparc (SPRC) Stock Up 47% Today? (InvestorPlace) +48.17%
08:01AM	SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation (GlobeNewswire)
Nov-10-23 09:10AM	SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication (GlobeNewswire) -8.52%
Oct-31-23 11:08AM	Why Is SciSparc (SPRC) Stock Up 58% Today? (InvestorPlace) +64.81%
07:38AM	SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology (GlobeNewswire)
Oct-24-23 07:20AM	SciSparc Granted Patent for its Core Technology From the Australian Patent Office (GlobeNewswire) -13.72%
Oct-17-23 08:00AM	Why Is SciSparc (SPRC) Stock Up 105% Today? (InvestorPlace) +124.56%
Oct-16-23 09:45AM	Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC) (ACCESSWIRE) -6.02%
08:17AM	SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Oct-13-23 04:28PM	SciSparc Ltd. Announces Closing of $5.026 Million Private Placement (GlobeNewswire) -9.67%
Oct-11-23 09:15AM	SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement (GlobeNewswire) -12.94%
Oct-03-23 07:33AM	SciSparc Granted European Patent for its Core Technology (GlobeNewswire) +38.59%
Sep-29-23 07:45AM	SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder (GlobeNewswire) -7.16%
Sep-27-23 07:58AM	SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split (GlobeNewswire) +32.86%
Sep-20-23 06:30AM	SciSparc Announces 1-for-26 Reverse Share Split (GlobeNewswire) +14.14%
Sep-12-23 09:15AM	SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities (GlobeNewswire) +6.38%
Sep-07-23 09:15AM	SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome (GlobeNewswire)
06:00AM	SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Aug-15-23 09:50AM	Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC) (ACCESSWIRE)
Aug-14-23 12:20PM	SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering (GlobeNewswire)
Aug-10-23 09:10AM	SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering (GlobeNewswire) -62.83%
Aug-09-23 04:40PM	SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million (GlobeNewswire) +11.24%
Aug-01-23 10:30AM	EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio (Benzinga)
09:00AM	SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S. (GlobeNewswire)
09:00AM	Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio (GlobeNewswire)
Jul-14-23 07:55AM	SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder (GlobeNewswire)
Jun-30-23 09:25AM	SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany (GlobeNewswire) -6.95%
Jun-21-23 10:30AM	EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US (Benzinga)
09:00AM	SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome (GlobeNewswire)
Jun-16-23 09:05AM	SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire) -5.27%
09:05AM	Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire)
Jun-07-23 08:05AM	SciSparc Grants an Exclusive License for the Sales of CannAmide on the Amazon Marketplace in Canada to SciSparc Nutraceuticals (GlobeNewswire)
08:05AM	Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide on the Amazon Marketplace in Canada (GlobeNewswire)
Jun-02-23 09:00AM	SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial (GlobeNewswire) -24.95%
May-30-23 08:40AM	SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP (GlobeNewswire)
May-08-23 06:35AM	SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program (GlobeNewswire)
May-02-23 07:25AM	SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation (GlobeNewswire) +6.46%
Apr-21-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression (GlobeNewswire) +12.28%
08:30AM	Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression (GlobeNewswire)
Apr-04-23 08:15AM	SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome (GlobeNewswire)
Mar-28-23 09:00AM	SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million (GlobeNewswire) -5.35%
Mar-10-23 04:15PM	SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Mar-09-23 07:30AM	SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome (GlobeNewswire)
Mar-06-23 07:45AM	SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome (GlobeNewswire)
Feb-27-23 09:11AM	SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder (GlobeNewswire) -11.64%
Feb-23-23 08:45AM	Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million (GlobeNewswire)
08:30AM	SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million (GlobeNewswire)
Feb-22-23 08:00AM	SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire) +6.64%
08:00AM	Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire)
Feb-17-23 08:00AM	SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System (GlobeNewswire) +9.89%
Feb-15-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US (GlobeNewswire)
08:30AM	Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US (GlobeNewswire)
Jan-25-23 08:30AM	SciSparc Announces Corporate Restructuring plan (GlobeNewswire) -5.15%
Jan-23-23 02:15PM	Small-Cap Companies Allege Illegal Short Selling (The Wall Street Journal) +17.16%
09:20AM	SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares (GlobeNewswire)
Jan-18-23 07:30AM	SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center (GlobeNewswire)
Jan-17-23 08:30AM	SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment (GlobeNewswire) +7.00%
Jan-09-23 08:30AM	SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center (GlobeNewswire)
Jan-05-23 09:00AM	SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial (GlobeNewswire) +12.88%
Dec-14-22 09:15AM	SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand (GlobeNewswire) -9.29%
Dec-07-22 08:40AM	SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy (GlobeNewswire) -7.41%
Nov-29-22 08:00AM	SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule (GlobeNewswire)
Nov-15-22 10:25AM	Can This Companys Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems? (News Direct)
09:15AM	SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line (GlobeNewswire)
Nov-08-22 07:00AM	SciSparc Gains Competitive Edge with Additional U.S. Patent Granted (GlobeNewswire)
Nov-07-22 08:45AM	SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimers Disease Patients with Agitation (GlobeNewswire)
Nov-01-22 08:30AM	SciSparc: Wellution Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms (GlobeNewswire) +12.09%

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRC

SciSparc Ltd

Upgrade your FINVIZ experience